At a glance
ClinicalIndex Comparison RecordN/ACompleted· 507 enrolled
Drug / intervention
Relugolixdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Description of Relugolix Use in Patients With Prostate Cancer: An Analysis of National Veterans Affairs Health Care Network Data
In Brief
An observational study evaluating Relugolix for Prostate Cancer. Completed, enrolled 507 participants across 1 site.
Detailed Summary
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20252026
First PostedJun 2024
Enrollment StartJun 2024
Primary CompletionDec 2024
TodayJul 2026
First PostedJun 17, 2024
Enrollment StartJun 19, 2024
Primary CompletionDec 13, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.0 years ago
Interventions
Relugolixdrug
relugolix